News

Video

Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC

Related Videos
Petros Grivas, MD, PhD; and Chandler Park, MD, MSc, FACP
Viktor Grünwald, MD, PhD
Daniel M. Halperin, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Timothy Yap, MBBS, PhD, FRCP
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"
Timothy Yap, MBBS, PhD, FRCP
Sumanta Kumar Pal, MD, FASCO,
A panel of 5 experts on lung cancer